Citations

Showing 10 of 108083 citations.

Glucose Homeostasis, Pancreatic Endocrine Function, and Outcomes in Advanced Heart Failure
Melenovský, Vojtěch , Beneš, Jan , Franeková, Janka , Kovar, Jan, Borlaug, Barry A. , Segeťová, Markéta , Pelikánová, T, Borlaug, Barry A , Kovář, Jan , Tura, Andrea , Melenovský, Vojtěch

Mayo Clinic

Journal of the American Heart Association | August 8, 2017 | Volume: 6 | Issue: 8 | Pages: No page available

10.1161/jaha.116.005290 | PMID 28784650 Get It

Background The mechanisms and relevance of impaired glucose homeostasis in advanced heart failure ( HF ) are poorly understood. The study goals were to examine glucose regulation, pancreatic endocrine function, and metabolic factors related to prognosis in patients with nondiabetic advanced HF. Methods and Results In total, 140 advanced HF patients without known diabetes mellitus and 21 sex‐, age‐, and body mass index–matched controls underwent body composition assessment, oral glucose tolerance testing, and measurement of glucose‐regulating hormones to model pancreatic β‐cell secretory response. Compared with controls, HF patients had similar fasting glucose and insulin levels but higher levels after oral glucose tolerance testing. Insulin secretion was not impaired, but with increasing HF severity, there was a reduction in glucose, insulin, and insulin/glucagon ratio—a signature of starvation. The insulin/C‐peptide ratio was decreased in HF , indicating enhanced insulin clearance, and this was correlated with lower cardiac output, hepatic insufficiency, right ventricular dysfunction, and body wasting. After a median of 449 days, 41% of patients experienced an adverse event (death, urgent transplant, or assist device). Increased glucagon and, paradoxically, low fasting plasma glucose displayed the strongest relations to outcome ( P =0.01). Patients in the lowest quartile of fasting plasma glucose (3.8–5.1 mmol·L −1 , 68–101 mg·dL −1 ) had 3‐times higher event risk than in the top quartile (6.0–7.9 mmol·L −1 , 108–142 mg·dL −1 ; relative risk: 3.05 [95% confidence interval, 1.46–6.77]; P =0.002). Conclusions Low fasting plasma glucose and increased glucagon are robust metabolic predictors of adverse events in advanced HF . Pancreatic insulin secretion is preserved in advanced HF , but levels decrease with increasing HF severity due to enhanced insulin clearance that is coupled with right heart failure and cardiac cachexia.
Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590)
Bhatia, Aarti , Lee, Ju‐Whei, Pinto, Harlan A. , Jacobs, Charlotte, Rubin, Philip, Arusell, Robert M., Dunphy, Eamonn P., Khandekar, Janardan D., Reiner, Seth A., Báez-Díaz, Luis , Celano, Paul , Li, Yi , Burtness, Barbara , Adams, George L. , Pandya, Kishan J., Bhatia, Aarti K , Limburg, Paul J. , Burtness, Barbara , Lee, Ju‐Whei , Li, Shuli

Mayo Clinic

Cancer | August 7, 2017 | Volume: 123 | Issue: 23 | Pages: 4653-4662

10.1002/cncr.30920 | PMID 28786105 Get It

BACKGROUND13‐Cis retinoic acid (13‐CRA) is a synthetic vitamin A derivative. High‐dose 13‐CRA in patients with squamous cell cancers of the head and neck (SCCHNs) reduces the incidence of second primary tumors (SPTs). The authors report long‐term results from a phase 3 randomized trial that compared treatment with low‐dose 13‐CRA versus placebo for patients who had early stage SCCHN, with a focus on the development of SPTs and overall survival (OS).METHODSIn total, 176 patients who received treatment for stage I/II SCCHN were randomized to receive either low‐dose 13‐CRA (weight‐based dose of 7.5 mg or 10 mg) or placebo for 2 years. A competing‐risk approach and the log‐rank test were used to compare the time to SPT and OS, respectively, between groups.RESULTS13‐CRA neither significantly reduced the cumulative incidence of SPT (P = .61) nor improved the time to SPT (hazard ratio [HR] for 13‐CRA/placebo; 0.86; P = .61). Despite limited power, there was a trend toward improved OS for the 13‐CRA arm (HR, 0.75; P = .14), particularly among patients whose index tumor was surgically excised (N = 26; HR, 0.50; P = .057) and among women (N = 39; HR, 0.44; P = .065) and never/former smokers (N = 129; HR, 0.61; P = .055), with a median follow‐up of 16 years. The main 13‐CRA related toxicities were dry skin and cheilitis.CONCLUSIONSTreatment with low‐dose 13‐CRA for 2 years did not decrease the incidence of SPT; subset analysis indicates a potential survival advantage among patients who are women and never/former smokers. More targeted interventions based on clinical risk factors and molecular characterization of tumors may yield greater success in future prevention trials. Cancer 2017;123:4653‐4662. © 2017 American Cancer Society.
Both DNA Polymerases δ and ε Contact Active and Stalled Replication Forks Differently
Yu, Chuanhe , Gan, Haiyun , Zhang, Zhiguo , Zhang, Zhiguo , Yu, Chuanhe

Mayo Clinic

Molecular and Cellular Biology | August 7, 2017 | Volume: 37 | Issue: 21 | Pages: No page available

10.1128/mcb.00190-17 | PMID 28784720 Get It

When Lightning Strikes
Cooper, Leslie T. , Cooper, Leslie T

Mayo Clinic

Circulation | August 7, 2017 | Volume: 136 | Issue: 6 | Pages: 546-548

10.1161/circulationaha.117.029340 | PMID 28784824 Get It

Total Artificial Heart: A Retrospective Multiple-Case Analysis of Occupational Therapy in a Quaternary Hospital
Oldenburg, Hannah , Bergstrom, Jennifer, Christensen, Gina, Polley, Caitlin A., Privette, R. Malcolm, Maureen, Musselmann, Pyffereon, Mary, Brannon, Charles

Mayo Clinic

American Journal of Occupational Therapy | August 7, 2017 | Volume: 71 | Issue: 1_suppl | Pages: No page available

10.5014/ajot.2017.71s1-po4068 Get It

Date Presented 3/31/2017 A retrospective multicase study of functional outcomes was done with patients with an implanted total artificial heart. Results show improved function with occupational therapy provided postoperatively. Knowledge and evidence can be used to develop and implement interventions for this population. Primary Author and Speaker: Hannah Oldenburg Additional Authors and Speakers: Jennifer Bergstrom, Gina Christensen Contributing Authors: Caitlin Polley, Randi Privette, Maureen Musselmann, Mary Pyffereon, Charles Brannon
Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort
Albert, Marilyn S. , Alonso, Álvaro , Coker, Laura H., Davis, Sonia M., Mosley, Thomas H., Sharrett, A. Richey , Windham, B. Gwen , Wruck, Lisa , Thomas, Sonia , Alonso, Alvaro , Gottesman, Rebecca F. , Coresh, Josef , Deal, Jennifer A. , McKhann, Guy M. , Mosley, Thomas H., Schneider, Andrea L.C. , Knopman, David S. , Wruck, Lisa M , Thomas, Sonia M

Mayo Clinic

JAMA Neurology | August 7, 2017 | Volume: 74 | Issue: 10 | Pages: 1246

10.1001/jamaneurol.2017.1658 | PMID 28783817 Get It

Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Krittanawong, Chayakrit , Sun, Tao , Herzog, Eyal

Mayo Clinic

Current Cardiology Reviews | August 7, 2017 | Volume: 13 | Issue: 4 | Pages: No page available

10.2174/1573403x13666170804152432 | PMID 28782493 Get It

Pneumonia and atrial flutter in a 71- year-old-man
Konik, Ewa, Sinak, Lawrence J., Wiley, Brandon M. , Sinak, Lawrence, Wiley, Brandon

Mayo Clinic

BMJ Case Reports | August 7, 2017 | Volume: 2017 | Issue: No issue available | Pages: bcr-2017-220691

10.1136/bcr-2017-220691 | PMID 28784891 Get It

Peer Review Certifies Quality and Innovation in Clinical Pharmacology & Therapeutics
Waldman, Scott A. , Waldman, Scott A , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | August 7, 2017 | Volume: 102 | Issue: 3 | Pages: 373-377

10.1002/cpt.763 | PMID 28782825 Get It

Clinical Pharmacology & Therapeutics (CPT) is an established voice of the discipline, a trusted source of new knowledge showcasing discovery, translation, and application of novel therapeutic paradigms to advance the management of patients and populations. Identifying, evaluating, prioritizing, and disseminating the best science along the discovery–development–regulatory–utilization continuum are responsibilities shared through peer review. To enhance the uniformity of this essential component of quality assurance and innovation, and maximize the value of the journal and its contents to authors, reviewers, and the readership, we review key concepts concerning peer review as it specifically relates to CPT.
Undetectable negative tissue transglutaminase IgA antibodies predict mucosal healing in treated coeliac disease patients
Larson, Joseph J. , Snyder, Melissa R. , Wu, T. T. , Murray, Joseph A. , Murray, J A , Fang, Hong , King, Katherine S. , Gandhi, Manish J.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 7, 2017 | Volume: 46 | Issue: 7 | Pages: 681-687

10.1111/apt.14250 | PMID 28782118 Get It

SummaryBackgroundTissue transglutaminase (tTG) immunoglobulin A (IgA) testing is a sensitive adjunct to the diagnosis of coeliac disease. The threshold for positivity was developed for diagnosis, with negative results reported as below the reference value (<4 U/mL).AimTo investigate if an undetectable (tTG IgA<1.2 U/mL) is more predictive of healing compared to patients with negative but detectable serology (1.2‐3.9 U/mL).MethodsWe performed a retrospective study of 402 treated coeliac disease patients seen at the Mayo Clinic with negative tTG IgA values drawn within 1 month of duodenal biopsy between January 2009 and December 2015. The Corazza‐Villanacci score was used to assess mucosal healing. The presence of gastrointestinal symptoms was also collected. Logistic regression was used to assess the relationship of clinical variables with a normal biopsy.ResultsPatients with undetectable titres more frequently had normal duodenal histology compared to patients with detectable tTG IgA levels (117/240 vs. 53/162; OR=1.96; 1.292, 2.961). Asymptomatic patients more frequently had normal duodenum as compared to symptomatic patients (88/163 vs. 82/239; OR=2.25; CI: 1.494, 3.377). Patients with undetectable serology and on a gluten‐free diet for ≥2 years were more likely to have no villous atrophy compared to patients with detectable serology (148/192 vs. 55/88; OR=2.02; CI: 1.17, 3.49).ConclusionIn subjects recovering from coeliac disease with negative tTG IgA serology, an undetectable titre is associated with normal histology on follow‐up biopsy.